180 related articles for article (PubMed ID: 32497973)
1. N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies.
Li M; Liu S; Chen H; Zhou X; Zhou J; Zhou S; Yuan H; Xu QL; Liu J; Cheng K; Sun H; Wang Y; Chen C; Wen X
Eur J Med Chem; 2020 Aug; 199():112279. PubMed ID: 32497973
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors.
Li P; Liu Y; Yang H; Liu HM
Eur J Med Chem; 2021 Apr; 216():113291. PubMed ID: 33684824
[TBL] [Abstract][Full Text] [Related]
3. An Integrated in silico Approach and in vitro Study for the Discovery of Small-Molecule USP7 Inhibitors as Potential Cancer Therapies.
Kanan D; Kanan T; Dogan B; Orhan MD; Avsar T; Durdagi S
ChemMedChem; 2021 Feb; 16(3):555-567. PubMed ID: 33063944
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of USP7 inhibition by selective small-molecule inhibitors.
Turnbull AP; Ioannidis S; Krajewski WW; Pinto-Fernandez A; Heride C; Martin ACL; Tonkin LM; Townsend EC; Buker SM; Lancia DR; Caravella JA; Toms AV; Charlton TM; Lahdenranta J; Wilker E; Follows BC; Evans NJ; Stead L; Alli C; Zarayskiy VV; Talbot AC; Buckmelter AJ; Wang M; McKinnon CL; Saab F; McGouran JF; Century H; Gersch M; Pittman MS; Marshall CG; Raynham TM; Simcox M; Stewart LMD; McLoughlin SB; Escobedo JA; Bair KW; Dinsmore CJ; Hammonds TR; Kim S; Urbé S; Clague MJ; Kessler BM; Komander D
Nature; 2017 Oct; 550(7677):481-486. PubMed ID: 29045389
[TBL] [Abstract][Full Text] [Related]
5. Discovery and characterization of highly potent and selective allosteric USP7 inhibitors.
Gavory G; O'Dowd CR; Helm MD; Flasz J; Arkoudis E; Dossang A; Hughes C; Cassidy E; McClelland K; Odrzywol E; Page N; Barker O; Miel H; Harrison T
Nat Chem Biol; 2018 Feb; 14(2):118-125. PubMed ID: 29200206
[TBL] [Abstract][Full Text] [Related]
6. Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro.
Jing B; Liu M; Yang L; Cai HY; Chen JB; Li ZX; Kou X; Wu YZ; Qin DJ; Zhou L; Jin J; Lei H; Xu HZ; Wang WW; Wu YL
Acta Pharmacol Sin; 2018 Mar; 39(3):492-498. PubMed ID: 29168472
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells.
Huang Y; Sun G; Wang P; Shi R; Zhang Y; Wen X; Sun H; Chen C
Bioorg Med Chem Lett; 2018 Sep; 28(17):2957-2960. PubMed ID: 30001917
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity.
Leger PR; Hu DX; Biannic B; Bui M; Han X; Karbarz E; Maung J; Okano A; Osipov M; Shibuya GM; Young K; Higgs C; Abraham B; Bradford D; Cho C; Colas C; Jacobson S; Ohol YM; Pookot D; Rana P; Sanchez J; Shah N; Sun M; Wong S; Brockstedt DG; Kassner PD; Schwarz JB; Wustrow DJ
J Med Chem; 2020 May; 63(10):5398-5420. PubMed ID: 32302140
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors.
Guo J; Zhao F; Yin W; Zhu M; Hao C; Pang Y; Wu T; Wang J; Zhao D; Li H; Cheng M
Eur J Med Chem; 2018 Jul; 155():197-209. PubMed ID: 29886323
[TBL] [Abstract][Full Text] [Related]
10. Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.
Wu J; Kumar S; Wang F; Wang H; Chen L; Arsenault P; Mattern M; Weinstock J
J Med Chem; 2018 Jan; 61(2):422-443. PubMed ID: 28768102
[TBL] [Abstract][Full Text] [Related]
11. USP7 small-molecule inhibitors interfere with ubiquitin binding.
Kategaya L; Di Lello P; Rougé L; Pastor R; Clark KR; Drummond J; Kleinheinz T; Lin E; Upton JP; Prakash S; Heideker J; McCleland M; Ritorto MS; Alessi DR; Trost M; Bainbridge TW; Kwok MCM; Ma TP; Stiffler Z; Brasher B; Tang Y; Jaishankar P; Hearn BR; Renslo AR; Arkin MR; Cohen F; Yu K; Peale F; Gnad F; Chang MT; Klijn C; Blackwood E; Martin SE; Forrest WF; Ernst JA; Ndubaku C; Wang X; Beresini MH; Tsui V; Schwerdtfeger C; Blake RA; Murray J; Maurer T; Wertz IE
Nature; 2017 Oct; 550(7677):534-538. PubMed ID: 29045385
[TBL] [Abstract][Full Text] [Related]
12. Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors.
Granchi C; Rizzolio F; Palazzolo S; Carmignani S; Macchia M; Saccomanni G; Manera C; Martinelli A; Minutolo F; Tuccinardi T
J Med Chem; 2016 Nov; 59(22):10299-10314. PubMed ID: 27809504
[TBL] [Abstract][Full Text] [Related]
13. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.
Li P; Liu HM
Eur J Med Chem; 2020 Apr; 191():112107. PubMed ID: 32092586
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
You H; Youn HS; Im I; Bae MH; Lee SK; Ko H; Eom SH; Kim YC
Eur J Med Chem; 2011 Apr; 46(4):1153-64. PubMed ID: 21330015
[TBL] [Abstract][Full Text] [Related]
17. Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.
Zhang W; Sartori MA; Makhnevych T; Federowicz KE; Dong X; Liu L; Nim S; Dong A; Yang J; Li Y; Haddad D; Ernst A; Heerding D; Tong Y; Moffat J; Sidhu SS
J Mol Biol; 2017 Nov; 429(22):3546-3560. PubMed ID: 28587923
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
19. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 2-aminopyridine derivatives as USP7 inhibitors.
Xu X; Wang M; Xu H; Liu N; Chen K; Luo C; Chen S; Chen H
Bioorg Chem; 2022 Dec; 129():106128. PubMed ID: 36113266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
